Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s1499-3872(15)60350-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chimeric antigen receptor-T cells targeting AFP-GPC3 mediate increased antitumor efficacy in hepatocellular carcinoma.
Arab J Gastroenterol
January 2025
Embryo Formation Teaching and Research Section, Guangxi University of Chinese Medicine, No.13 Wuhe Avenue, Nanning 530200, Guangxi, China.
Background And Study Aims: As a novel immunotherapy, chimeric antigen receptor T (CAR-T) cell technology is successful in treating hematologic malignancies, and exhibits potential benefits in partial solid tumors. Therapies targeting one antigen have some weaknesses, and dual-targeted CAR-T cells may be a better option. Alpha-fetoprotein (AFP) and glypican-3 (GPC3) are both highly expressed in hepatocellular carcinoma (HCC) and serve as important markers.
View Article and Find Full Text PDFRapid evaluation of hepatocellular carcinoma by detecting plasma exosomes with time-resolved fluorescence immunochromatographic test strips.
Mikrochim Acta
December 2024
School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong, China.
Article Synopsis
- A new test called Time-resolved fluorescence immunochromatographic test strips (TRFIS) has been created for the fast detection of a specific type of exosome related to liver cancer, targeting a protein called glypican-3 (GPC3).
- The test allows for direct detection of these exosomes in plasma without needing complex isolation methods, completing the entire process in just 15 minutes.
- Clinical testing showed that TRFIS can effectively differentiate HCC patients from healthy individuals with high sensitivity and specificity, presenting a promising tool for early liver cancer screening.
GPC-3 in hepatocellular carcinoma; A novel biomarker and molecular target.
Exp Cell Res
December 2024
Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden; Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Department of Cellular and Molecular Biology, Faculty of Sciences and Advanced Technology in Biology, University of Science and Culture, Tehran, Iran. Electronic address:
Article Synopsis
- Hepatocellular carcinoma (HCC) is a significant global health concern, characterized by late diagnosis and high recurrence rates, necessitating early detection through specific biomarkers.
- Glypican-3 (GPC-3) is identified as a promising biomarker for HCC, being overexpressed in various tumors, which opens up opportunities for targeted therapies to enhance treatment outcomes.
- Recent advancements in GPC-3-targeted therapies, such as bi-specific antibodies and CAR T cell therapies, underscore its potential as both a diagnostic and therapeutic tool in the fight against HCC.
Synthesis and Preclinical Evaluation of Dual-Specific Probe Targeting Glypican-3 and Prostate-Specific Membrane Antigen for Hepatocellular Carcinoma PET Imaging.
Mol Pharm
January 2025
Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Positron emission tomography (PET) is a promising modality for early diagnosis, accurate detection, and staging of hepatocellular carcinoma (HCC). Hereby, a dual-specific probe targeting Glypican-3 (GPC3) and prostate-specific membrane antigen (PSMA) was evaluated for HCC PET imaging. The probe was prepared by conjugating TJ12P2, a GPC3-targeting peptide previously reported by our group, to a highly potent PSMA inhibitor via a polyethylene glycol linker and further tethered to the 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) chelator.
View Article and Find Full Text PDFThe anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.
Nanomedicine (Lond)
January 2025
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, Italy.
Background: Recently, we developed AT101, an IgM-class mouse monoclonal antibody directed against glypican-1 (GPC1), a proteoglycan that can be considered as useful target for glioblastoma multiforme (GBM) treatment being specifically and highly expressed on GBM cell surface. Here, we proposed the use of AT101 as targeting agent in a drug delivery nanoplatfom to effectively deliver chitosan nanobubbles (NBs) for GBM treatment.
Methods: Chitosan NBs were prepared and conjugated with AT101 or left unconjugated as control.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!